{"url_path":"/sec/fth/8-k/2026-05-15/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1829802/0001193125-26-225323-index.html","accession_number":"0001193125-26-225323","cik":"0001829802","ticker":"FTH","issuer_name":"Faeth Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1829802/0001193125-26-225323-index.html","primary_entity_key":"0001829802","primary_entity_name":"Sensei Biotherapeutics, Inc."},"word_count":89,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit\nNumber\n\n  \n\nExhibit Description\n\n99.1\n  \n[Press Release of Sensei Biotherapeutics, Inc., dated May 15, 2026](d125741dex991.htm)\n\n104\n  \nThe cover page from this Current Report on Form 8-K, formatted in Inline XBRL\n\n \n\n2\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \nSensei Biotherapeutics, Inc.\n\nDate: May 15, 2026\n \n\n \n \n \n\n/s/ Christopher W. Gerry\n\n \n\n \n\n \nChristopher W. Gerry\n\n \n\n \n\n \nGeneral Counsel and Secretary\n\n \n\n3"}